Scientists and patient advocates have largely overlapping agendas, but, ultimately, their agendas diverge, said Fran Visco, president of the National Breast Cancer Coalition, the organization that ushered in a new era in the politics of cancer research and delivery of care.
In 1999, Richard Pazdur, a GI oncologist at MD Anderson, saw an FDA recruitment ad in The New England Journal of Medicine. The agency was looking for a director of the FDA Division of Oncology Drug Products.
